A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Carboplatin (Primary) ; Catequentinib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ALTER-GO-010
- 02 Jul 2024 Planned End Date changed from 1 Dec 2024 to 31 Dec 2027.
- 02 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 30 Sep 2025.
- 02 Jul 2024 Status changed from recruiting to active, no longer recruiting.